Zobrazeno 1 - 10 of 446 pro vyhledávání: '"M. Van-Ham"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections.
Autor: Ferdy R van Diemen, Elisabeth M Kruse, Marjolein J G Hooykaas, Carlijn E Bruggeling, Anita C Schürch, Petra M van Ham, Saskia M Imhof, Monique Nijhuis, Emmanuel J H J Wiertz, Robert Jan Lebbink
Publikováno v: PLoS Pathogens, Vol 12, Iss 6, p e1005701 (2016)
Herpesviruses infect the majority of the human population and can cause significant morbidity and mortality. Herpes simplex virus (HSV) type 1 causes cold sores and herpes simplex keratitis, whereas HSV-2 is responsible for genital herpes. Human cyto
Externí odkaz: https://doaj.org/article/db8826bb2d64482da576a163cd3174c7
Zobrazit plný text záznamu
5
Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients:To wait and repopulate?
Autor: Eva M.M. Strijbis, A. ten Brinke, P. J. van Dam, Gertjan Wolbink, Alyssa A. Toorop, Sander W. Tas, Laura Y Kummer, Niels J. M. Verstegen, A. G. Volkers, Z.L.E. van Kempen, Mark Löwenberg, S. M. van Ham, Taco W. Kuijpers, T. Rispens, Joep Killestein, Laura Boekel, Luuk Wieske, Filip Eftimov, Maurice Steenhuis, C. E. van de Sandt, Eileen W Stalman
Publikováno v: T2B! immunity against SARS-CoV-2 study group 2022, ' Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients : To wait and repopulate? ', Multiple Sclerosis and Related Disorders, vol. 57, 103416, pp. 103416 . https://doi.org/10.1016/j.msard.2021.103416
Multiple sclerosis and related disorders, 57:103416. Elsevier
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 57:103416. Elsevier
Multiple Sclerosis and Related Disorders, 57:103416. Elsevier
Multiple Sclerosis and Related Disorders
OBJECTIVE: The objective of this study was to measure humoral responses after SARS-CoV-2 vaccination in MS patients treated with ocrelizumab (OCR) compared to MS patients without disease modifying therapies (DMTs) in relation to timing of vaccination
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bce230db5b98b1f7713bab926997858
https://research.vumc.nl/en/publications/63937a74-3372-48c4-a013-8baffc018345
Zobrazit plný text záznamu
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Clinical auditing as an instrument to improve care for patients with ovarian cancer
Autor: N. Leffers, H.T.C. Nagel, Roy F.P.M. Kruitwagen, R.A. Smit, F.A. Ten Cate, A.D. Ten Cate, S.F.P.J. Coppus, A.M.L.D. Van Haaften-de Jong, J.H.A. Vollebergh, M.J.A. Engelen, Eva Maria Roes, L.C. De Vries, P.J. Timmers, E.A. Ooms, J. Diepstraten, G.H. Jansen, W. Minderhoud-Bassie, N.M.S. Baldewpersad Tewarie, M.I. Baas, M.A. van der Aa, M. van Ham, A.J. Kruse, T.K. Schikken, T.C. Stam, I.M.W. Ebisch, J.A. Louwers, J.W. Mens, A.M.G. van de Swaluw, E. Davelaar, C.G. Gerestein, M.W. Glas, R. van de Laar, B.A.J.T. Visschers, H.P.M. Smedts, W.J. van Driel, E.B.L. van Dorst, R. Yigit, M.W.G. Moonen Delarue, W.M. van Baal, Y.W.C.M. Van der Plas – Koning, M.Y. Tjiong, L.R. Bartelink, F.M.F. Rosier-van Dunné, M.B. Verbruggen, J.G. Lange, Michel W.J.M. Wouters, C.M.W.H. Smeets, G. Fons, F.E.M. Rijcken, H.R. Verhoeve, J.W.D. de Waard, E.J.M. Van Es, J.E.W. Van Dijk, J. Briet, C.C.M. Buis, K. Overmars, A. van der Kolk, M. Kleppe, M.A. Huisman, P. Kolk, E.J.M. Robbe, M. van den Hende, M. Huisman, Brigitte F. M. Slangen, A.L. Aalders, S.M. Westenberg, H.H. Keizer, M.C. Vos, A. Baalbergen, L.N. Hofman, J. Kaijser, D. Boll, N. Reesink, D. Boskamp, P.M.L.H. Vencken, K.N. Gaarenstroom, D.H. Ngo, M.D. Wust
Publikováno v: European Journal of Surgical Oncology, 47(7), 1691-1697. W.B. Saunders
European Journal of Surgical Oncology, 47, 7, pp. 1691-1697
European Journal of Surgical Oncology, 47, 1691-1697
European Journal of Surgical Oncology, 47(7), 1691-1697. ELSEVIER SCI LTD
European Journal of Surgical Oncology, 47(7), 1691-1697. W.B. Saunders Ltd
European journal of surgical oncology, 47(7), 1691-1697. W.B. Saunders Ltd
EJSO-European Journal of Surgical Oncology, 47(7), 1691-1697. ELSEVIER SCI LTD
participants of the Dutch Gynecological Oncology Collaborator Group 2021, ' Clinical auditing as an instrument to improve care for patients with ovarian cancer: The Dutch Gynecological Oncology Audit (DGOA) ', European Journal of Surgical Oncology, vol. 47, no. 7, pp. 1691-1697 . https://doi.org/10.1016/j.ejso.2021.01.019
Introduction: The Dutch Gynecological Oncology Audit (DGOA) was initiated in 2014 to serve as a nationwide audit, which registers the four most prevalent gynecological malignancies. This study presents the first results of clinical auditing for ovari
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05397eadfd4449c5d34008662c18454f
https://hdl.handle.net/1887/3276128
Zobrazit plný text záznamu
10
Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA)
Autor: MC Vos, H.T.C. Nagel, R.A. Smit, N. Reesink, A. Baalbergen, Eva Maria Roes, P.J. Timmers, Arnold-Jan Kruse, Jan Willem M. Mens, Mirjam J. A. Engelen, B.A.J.T. Visschers, T.C. Stam, H.P.M. Smedts, N.M.S. Baldewpersad Tewarie, A. van der Kolk, J. Lange, H. Verhoeve, Katja N. Gaarenstroom, Michel W.J.M. Wouters, Brigitte F. M. Slangen, I. Ebisch, Sjors F.P.J. Coppus, D. Boll, L. Hofman, C. G. Gerestein, Y.W.C.M. van der Plas-Koning, J. de Waard, A.M.L.D. van Haaften-de Jong, E.B.L. van Dorst, J. Diepstraten, A.D. Ten Cate, M.Y. Tjiong, M.A. van der Aa, R. Yigit, A.L. Aalders, R Kruitwagen, J. Briet, W.J. van Driel, M. van Ham, P.M.L.H. Vencken, M.B. Verbruggen, M. Huisman, Guus Fons
Publikováno v: Gynecologic Oncology, 162(2), 331-338. Elsevier Science
Gynecologic Oncology, 162, 2, pp. 331-338
Gynecologic Oncology, 162, 331-338
On behalf of the participants of the Dutch Gynecological Oncology Collaborator Group 2021, ' Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) ', Gynecologic Oncology, vol. 162, no. 2, pp. 331-338 . https://doi.org/10.1016/j.ygyno.2021.05.030
Gynecologic oncology, 162(2), 331-338. Academic Press Inc.
Gynecologic Oncology, 162(2), 331-338. Academic Press Inc.
Gynecologic Oncology, 162(2), 331-338. ACADEMIC PRESS INC ELSEVIER SCIENCE
Gynecologic Oncology, 162(2), 331-338. Academic Press
Objectives. The challenge when performing cytoreductive surgery (CRS) is to balance the benefits and risks. The aim of this study was to report short term postoperative morbidity and mortality in relation to surgical outcome in patients undergoing pr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ea3ca6a5e9699a01b8fa682b8f2669f
https://doi.org/10.1016/j.ygyno.2021.05.030
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje